advanced renal cell carcinoma

Merck's Best Seller Keytruda Racks Up Another Regulatory Win
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
BioSpace
Merck
Keytruda
advanced renal cell carcinoma
renal cell carcinoma
Eisai
Lemvima
FDA
Flag link:
Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC
Exelixis Gets FDA Approval for Cabometyx in Combination Therapy for Front-Line RCC
Motley Fool
Exelixis
FDA
Cabometyx
Cometriq
advanced renal cell carcinoma
Flag link:
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?
BioSpace
Merck
Eisai
Keytruda
Lenvima
clinical trials
advanced renal cell carcinoma
Flag link:
Merck and Pfizer’s Bavencio approved for renal cell carcinoma
Merck and Pfizer’s Bavencio approved for renal cell carcinoma
Pharmaforum
Merck KGaA
Pfizer
Bavencio
FDA
Inlyta
advanced renal cell carcinoma
Flag link:
Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma
Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma
Pharmaceutical Business Review
Exelixis
clinical trials
cabozantinib
Cabometyx
advanced renal cell carcinoma
Flag link:
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
Merck Wins FDA Nod for Combo Therapy in Advanced Kidney Cancer
Xconomy
Merck
FDA
Keytruda
kidney cancer
advanced renal cell carcinoma
Inlyta
Flag link:
Aveo stock plunges after delay in FDA approval submission for cancer drug
Aveo stock plunges after delay in FDA approval submission for cancer drug
Bizjournals
Aveo Oncology
kidney cancer
FDA
tivozanib
advanced renal cell carcinoma
Flag link:
National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma
National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma
CP Wire
Exelixis
Cabometyx
advanced renal cell carcinoma
Flag link:
National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma
Exelixis
Cabometyx
advanced renal cell carcinoma
Flag link:
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Exelixis
Ipsen
Cabometyx
advanced renal cell carcinoma
renal cell carcinoma
Flag link:
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Yahoo
Exelixix
Ipsen
clinical trials
advanced renal cell carcinoma
Cabometyx
ASCO 2016
Flag link:
Eisai's kidney drug wins expanded indication in the U.S.
Eisai's kidney drug wins expanded indication in the U.S.
BioPharma Dive
Eisai
advanced renal cell carcinoma
kidney cancer
Lenvima
RCC
Flag link: